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Abstract
Background: The applications of massively parallel sequencing technology to fetal cell-free DNA (cff-DNA) have
brought new insight to non-invasive prenatal diagnosis. However, most previous research based on maternal
plasma sequencing has been restricted to fetal aneuploidies. To detect specific parentally inherited mutations,
invasive approaches to obtain fetal DNA are the current standard in the clinic because of the experimental
complexity and resource consumption of previously reported non-invasive approaches.
Methods: Here, we present a simple and effective non-invasive method for accurate fetal genome recovery-
assisted with parental haplotypes. The parental haplotype were firstly inferred using a combination strategy of trio
and unrelated individuals. Assisted with the parental haplotype, we then employed a hidden Markov model to
non-invasively recover the fetal genome through maternal plasma sequencing.
Results: Using a sequence depth of approximately 44X against a an approximate 5.69% cff-DNA concentration, we
non-invasively inferred fetal genotype and haplotype under different situations of parental heterozygosity. Our data
show that 98.57%, 95.37%, and 98.45% of paternal autosome alleles, maternal autosome alleles, and maternal
chromosome X in the fetal haplotypes, respectively, were recovered accurately. Additionally, we obtained efficient
coverage or strong linkage of 96.65% of reported Mendelian-disorder genes and 98.90% of complex disease-
associated markers.
Conclusions: Our method provides a useful strategy for non-invasive whole fetal genome recovery.
Background
Prenatal diagnosis is one of the most efficient approaches
to decrease the incidence of birth defects [1]. Traditionally,
fetal cells for prenatal diagnosis are collected invasively by
the procedures of amniocentesis or chorionic villus sam-
pling (CVS), but these carry a risk of miscarriage [2,3]. To
reduce the requirement of invasive testing, non-invasive
approaches, such as the use of maternal serum markers
and ultrasound, are widely used in the clinic to classify
low- and high-risk pregnant women with Down’s
syndrome fetuses. However, these non-invasive prenatal
screens are unsatisfactory to many clinicians and pregnant
women due to their false-positive and potential false-nega-
tive rates [4-6]. With the discovery of cell-free fetal DNA
(cff-DNA) in maternal plasma [7-10] and the emergence
of high-throughput sequencing, the clinical application of
non-invasive tests to detect fetal chromosomal abnormal-
ities using maternal plasma sequencing have been dis-
cussed [11-13].
Theoretically, it should be possible to recover the fetal
genome non-invasively through maternal plasma sequen-
cing to enable the comprehensive prenatal diagnosis of
Mendelian diseases and lessen the need for invasive proce-
dures [14,15]. In 2010, Lo’s group showed the feasibility of
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non-invasive fetal whole genome recovery and inferring
the fetal genotype, although they did not assess the bipar-
entally heterozygous sites in the fetal genome [14]. Recent
studies from Kitzman et al. [15] and Fan et al. [16] intro-
duced accurate non-invasive fetal genotype inference
methods assisted by maternal haplotype, but their meth-
ods showed uncertain performance in detecting paternal
transition in low cff-DNA concentrations. In early gesta-
tion, the concentration of cff-DNA is approximately 3% to
6% of the total cell-free DNA [17], which may lead to
uneven recovery of the paternal allele in the whole gen-
ome. Robust strategies of noninvasively detecting both
maternal and paternal alleles are still needed. Moreover,
the fetal haplotype information is especially useful in
detecting some haplotype-related diseases, such as sys-
temic lupus erythematosus [18], as well as personal geno-
mic analyses in the future [19,20].
Here, we developed a novel strategy of fetal genome
recovery, inferring the fetal genotype as well as haplo-
type at the same time. Given the fact that the fetal gen-
ome is the combination of parentally transmitted
chromosomes, we reconstructed the fetal genome by
observing parental allele transition in maternal plasma.
We first used a combined strategy of trios and unrelated
individuals to construct parental haplotypes, and then
observed the parental allele transition in maternal
plasma and optimized the fetal haplotype using a hidden
Markov model (HMM) and Viterbi algorithm. Thereby,
we recovered the fetal haplotype as well as the genotype
against all parental heterozygosity in one step. Our
method highlights the prospective value to translational
medicine of non-invasive prenatal diagnosis to recover
the fetal genome using maternal plasma sequencing.
Methods
Sample preparation
In this study, a Chinese couple and both parents of the
couple were recruited with written informed consent.
Also, this study was approved by the institutional review
board of BGI-Shenzhen and conducted in accordance
with the Declaration of Helsinki.
Peripheral blood
We collected 10 mL of peripheral blood from a woman
with pregnancy of 13 weeks of gestation, 5 mL of per-
ipheral blood from her husband, and 10 mL of fetal
umbilical blood after the delivery. Blood samples from
each participant were collected in EDTA-containing
tubes.
Maternal plasma
We obtained maternal plasma from 10 mL maternal per-
ipheral blood after centrifugation at 1,600 g for 10 min.
Great care was taken in the collection of plasma samples
to avoid taking the buffy coat or any blood clots. Plasma
was transferred to 2.0 mL eppendorf tubes and centri-
fuged at 16,000 g for 10 min to remove residual cells.
Blood samples and plasma samples were stored at -20°C
and -80°C, respectively, until further processing.
Saliva
Saliva was collected from grandparents using Oragene ®
OG-250 tubes and kits, following the standard manufac-
turer’s instructions.
DNA extraction
g-DNA from whole blood, saliva, and maternal plasma
were extracted by using a TIANamp Micro DNA Kit
(Tiangen) according to the manufacturer’s instructions.
Library preparation and massively parallel genomic
sequencing
Genomic DNA
One microgram of g-DNA was sheared by an S2 sonica-
tor (Covaris, Inc.), yielding fragments between 100 and
500 bp, with a predominance of 300 bp. For massively
parallel genomic sequencing, approximately 1 μg of frag-
mented g-DNA was prepared for library construction.
Briefly, DNA fragments were blunt-ended using T4
DNA polymerase (Enzymatics), Klenow polymerase
(Enzymatics), and T4 polynucleotide kinase (Enzymatics)
and were ligated to adapters after addition of terminal A
nucleotides. The adapter-ligated DNA fragments in the
range of 300 to 350 bp were size-selected using 2% agar-
ose electrophoresis and then amplified using a 10-cycle
PCR. An Agencourt AMPure 450 mL Kit was used for
the purification of PCR products.
Plasma DNA
Plasma DNA (10 to 50 ng) was used for library prepara-
tion according to a modified protocol, in which a 17-
cycle PCR was conducted to enrich adapter-ligated
DNA fragments.
Library QC and sequencing
The libraries were quality-controlled by using an Agilent
DNA 1000 kit on the 2100 Bioanalyzer (Agilent) plat-
form and quantified by real-time PCR. DNA libraries
were hybridized to the surface of sequencing flowcells,
and DNA clusters were generated after amplification.
The libraries were then sequenced using the Illumina
Hiseq™ 2000 sequencing system according to the man-
ufacturer’s instructions. The sequence reads of this par-
ent-offspring trio have been uploaded to the NCBI SRA
database (SRA060043).
Illumina DNA microarray
The construction of the library and scanning of the
microarray (Omni 2.5 SNP-array) were done according
to the manufacturer’s instructions for the corresponding
array and for Iscan.
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Bioinformatics
Bioinformatic analyses are described in the Additional
file 1 (Additional file 1, Supplementary Methods).
Results
Accurate fetal genome recovery through maternal plasma
To perform haplotype-assisted accurate non-invasive
fetal whole genome recovery through maternal plasma
sequencing (Figure 1), we recruited a Chinese woman
with pregnancy of 13 weeks of gestation and her family,
including three generations, as well as fetal blood after
delivery. We then performed approximately 44X and
20X whole genome shotgun sequencing of the plasma
sample and of parental genomic DNA (g-DNA), respec-
tively (Table 1). The cff-DNA concentration of this male
fetus was estimated as 5.69% using the biparentally
homozygous sites. Illumina Infinium HD Human610-
Quad BeadChip was used to genotype the gDNA from
grandparents to construct the parental haplotypes. Also,
we used Illumina HumanOmni2.5-8 BeadChip to vali-
date the accuracy of parental SNP calling, in which the
parental genotypes were validated as approximately
99.22% consistent with the array (Table 1 and Addi-
tional file 1, Table S1).
We then performed a parental haplotype construction
with a combined strategy of trios and unrelated indivi-
duals. Although both trios and unrelated individuals could
be applied to construct the parental haplotypes, the haplo-
type ambiguity in trio strategy and the stratification in
unrelated individual strategy would significantly restrict
the value of either of these strategies. In this study, the
parental haplotypes were obtained by BEAGLE [21] using
their sequencing genotype and the genotyping data of the
grandparents along with the newly released 51 parent-off-
spring trios of Chinese Han in the 1000 Genomes project
(pilot II). By using this strategy, the inferred rate of paren-
tal haplotypes increased, on average, from 90.32% to 100%
compared to using a trio strategy only.
Assisted by the parental haplotypes, we then devel-
oped an efficient method for fetal whole genome recov-
ery through maternal plasma sequencing. Ideally, in
maternal plasma sequencing with a site-by-site strategy
(SBSS), we could reconstruct the paternally transmitted
allele directly by determining the nucleotide sequence of
the paternal-specific allele at paternal-only heterozygous
sites and determine the maternal transition by observing
allelic imbalance at individual sites. However, the appli-
cation of this simple idea could be hinderedby low cff-
DNA concentration and sequence depth. In our plasma
sequencing, approximately 57.84% of the paternal-speci-
fic alleles were totally absent (Figure S3). Additionally,
our estimation of the concentrations of three different
alleles in plasma showed that 24,938 of 137,567
(25.40%) sites showed an opposite allelic imbalance
(Additional file 1, Supplementary Materials). These
results indicate the infeasibility of SBSS in samples with
low cff-DNA concentration and sequence depth. Thus,
we introduced a sensitive HMM to identify the paren-
tally transmitted allele and recombination breakpoints
(Figure 2 and Additional file 1, Supplementary Meth-
ods), in which we predicted the fetal haplotype on the
paternal-only, maternal-only, and biparentally heterozy-
gous sites in one step. With the use of the HMM and
Viterbi algorithm, the fetal haplotypes of the 374,980
markers (including chromosome X) were recovered suc-
cessfully (Table 2).
Figure 1 The research principle of our study. To recover the fetal genome, we divided our work into several parts. We first recruited a family
that included three entire generations. The parental genotypes were determined by whole genome sequencing, whereas the grandparents’
were determined by SNP array. We then constructed parental haplotypes with a combined trio and unrelated-individual strategy. Assisted by the
parental haplotypes, we successfully recovered the fetal genome via maternal plasma DNA sequencing. Finally, we performed a validation using
the child’s cord blood after the delivery.
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Accuracy of the recovered fetal haplotype
We performed a final validation to estimate the overall
accuracy of the predicted fetal haplotype. To assess the
standard fetal haplotype, we also performed a whole
genome sequencing of the cord blood obtained after the
child’s birth to approximately 20-fold coverage (Table 1
and Additional file 1, Table S1). The genotypes of the
child were determined using SOAPsnp and were vali-
dated at 99.25% consistency with his genotyping of
HumanOmni2.5-8 BeadChip. The standard haplotype of
the child was inferred by the same method as used for
his parents. Finally, the general accuracy of the paternal
alleles and maternal alleles were estimated by comparing
the recovered fetal genome with the standard haplotype
Table 1 Data production
Microarray array
Samples Type of DNA Type of microarray Call rate (%) SNP calling (n) (105)
Grandparentsa g-DNA (saliva) Human 610-Quad BeadChip 99.70 ± 0.07 5.89 ± 0.004
WGS












Father g-DNA (blood) 0.72 71.89 89.75 99.71 21.86 99.23
Mother g-DNA (blood) 0.74 74.03 90.19 99.09 20.96 99.19
Offspring g-DNA (cord
blood)
0.72 72.17 90.64 99.75 21.32 99.25
Plasma Plasma DNA 1.81 179.63 83.68 99.47 43.91 -























    Maternal allele





Allele 0 Allele 1Predicted
Fetal Haplotype Allele 0
Figure 2 Identification of recombination breakpoints by HMM. This figure shows the HMM-based detection of recombination and the
predicted fetal haplotype. A genomic region from on Chr3 (120-150 Mb) is shown with lines (red for paternal allele, blue for maternal allele)
indicating the logarithmic odds ratio between transmission probability of haplotype 1 and haplotype 0, which were computed by the HMM at
each site. The color-coded chart (top) shows the predicted fetal haplotype as a combination of parental alleles.
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of the child (Table 2). For the recovered paternal alleles,
105,729 loci of our recovery were consistent with the
standard haplotype, indicating a high accuracy of
98.57%. For the recovered maternal autosomal alleles,
103,082 loci were consistent with the standard haplo-
type, for a slightly lower accuracy of maternal allele
recovery of 95.37%. The maternal allele recovery on the
chromosome X showed an accuracy of 98.45% (1,902/
1,932 loci).
We further classified the recovery errors into different
types (Table 2). Type I errors, which were randomly dis-
tributed throughout the whole genome, explained
95.36% and 28.81% of paternal and maternal recovery
inaccuracies, respectively. We assume that type I errors
were caused by the haplotype ambiguity during the par-
ental or standard fetal haplotype inference. The type II
errors, which mostly clustered next to the recovered
recombination breakpoints, were most probably caused
by the inaccuracy of recombination breakpoint recovery.
This type of error explained the remaining 4.64% of the
paternal allele recovery inaccuracies, 65.83% of the
maternal autosome allele recovery mistakes, and 80.00%
of chromosome X recovery mistakes, indicating difficul-
ties in maternal recombination breakpoint determina-
tion. The rest, referred to as type III errors, were related
to heterochromatin close to the centromeres or chromo-
some ends. Type III errors explained 5.35% of maternal
autosome and 20.00% of chromosome X maternal allele
recovery errors (Additional file 1, Table S5).
To estimate the correlation between sequencing data
and the detection accuracy of the recovered fetal genome,
we sampled a subset of data from the maternal plasma
sequencing (Figure 3). Generally, the accuracy of the
recovered fetal genome increased with the depth of
maternal plasma sequencing. Because of the existence of
type I errors, the accuracy began to stabilize when the
sequence depth grew >20X. Additionally, the accuracy of
the paternal-only heterozygous sites indicated the robust-
ness of our method for paternal allele recovery in low cff-
DNA concentrations among different sequence depths.
For example, using only 6% of the plasma sequence data
(non-duplicate approximately 2.01X), we successfully
recovered 97.61% of the maternal-only heterozygous
sites.
In summary, 98.57% of the paternal alleles, 95.37% of
the maternal autosomes and 98.45% of the chromosome
X were recovered precisely using approximately 43.91X
(non-duplicate approximately 33.60X) maternal plasma
sequencing with a 5.69% cff-DNA concentration. The
quality of haplotype interference, the accuracy of the
recombination breakpoint prediction, and heterochroma-
tin close to centromeres and chromosome ends explained
most of our recovery errors. The simulations suggested
the robustness of our method at lower sequence depth
and low cff-DNA concentration, especially for paternal
allele recovery.
The application of non-invasive fetal genomics
Inheritable genetic disease screening and Mendelian
character predictions are two important applications of
accurate fetal genome recovery. So far, 7,895 pathogenic
genes related to Mendelian diseases have been released
by OMIM (Online Mendelian Inheritance in Man [22]),
96.65% of which were directly covered by or strongly
linked with our 374,980 effective marker loci. In the
case of complex diseases, 98.90% of 6,939 disease-asso-
ciated loci from the NHGRI GWAS Catalog [23] were
directly covered by or strongly linked with our marker
loci. Interestingly, a TC genotype at rs17822931 (Chr16:
46,815,699; predicted accurately) is consistent with the
offspring having earwax of the wet type [24], which is
not typical in Asians and Native Americans [25]. The
level of throughput of disease and trait screening implies
that noninvasive prenatal diagnosis/screening can have
high detection efficiency. The strategy of using three
generations of a family increased the robustness of
detecting rare mutations, showing a similar performance
between common mutations and rare mutations (Addi-
tional file 1, Figure S4). Moreover, based on our accu-
rate recovered haplotype, heritable complex variations
Table 2 The general accuracy of haplotype prediction
Category Paternal allele Maternal allele
Autosome Autosome ChrX






Inconsistent with g-DNA from cord
blood
Loci (n, percentage) 1,529 (1.43%) 5,005 (4.63%) 30 (1.55%)
Type I (noisy from haplotype inference) 1,458 (95.36%) 1,442 (28.81%) -
Type II (recombination breakpoint related) 71 (4.64%) 3,295 (65.83%) 24 (80.00%)
Type III (centromere or chromosome edge
related)
0 (0%) 268 (5.35%) 6 (20.00%)
Total 107,258 108,087 1,932
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(such as long insertions/deletions, translocations, rear-
rangements, and even disease-related methylation),
unlike SNPs, which were hard to observe directly in
maternal plasma, could be mapped to the fetal genome
by their linkage disequilibrium relationships using other
existing techniques.
Discussion
Here we report a haplotype-assisted approach for non-
invasive fetal whole genome recovery. The characteristics
of our method and two previously reported haplotype-
assisted methods [15,16] are summarized in Table 3. We
further assessed the fetal genotype accuracy to compare
the practical performance in corresponding cases to
reach comprehensive conclusions (Table 4).
Three fetal genome recovery strategies have employed
parental haplotypes, but with different inference strate-
gies. We used a common genetics approach to determine
the parental haplotypes by using the genotyping data of
surviving grandparents or born offspring. This approach
provided a practical strategy for non-invasive fetal gen-
ome screening for families with probands, especially for
families with born offspring with Mendelian diseases.
However, this specific sample recruitment would restrict
its prospects for clinical application. To overcome this
limitation, Kitzman et al. [26] and Fan et al. [27] have
constructed maternal haplotypes directly using noninva-
sive experimental approaches. However, the time and
resource consumption of their complex experimental
methods would restrict their clinical application. For
example, it would take approximately 8 days and another
US$3,678 to prepare the fosmid clone library [26].
Second, these three strategies all used the maternal
haplotype, but we used the paternal haplotype. For pater-
nal-only heterozygous sites, Kitzman et al. performed
SBSS to detect the paternal-specific allele. In SBSS, one
or more reads matching the paternal-specific allele are
taken as evidence of its transition. However, the perfor-
mance of SBSS depends on cff-DNA concentration and
sequence depth. For example, 96.80% of alleles in the trio
labeled I1 in the Kitzman et al. study (WGS approxi-
mately 78X, cff-DNA concentration approximately 13%)
were predicted correctly. However, in the case of low cff-
DNA concentration, such as trio G1 (WGS approxi-
mately 56X, at 8.14 weeks) reported by Kitzman et al.,
only 60.3% of paternal-specific alleles were identified cor-
rectly. Therefore, Fan et al. imputed the paternal allele
using data from the 1000 Genomes project. In total,
approximately 70% of the paternally transmitted alleles
were reconstructed with an accuracy of 93% to 97%. This
implied the imperfect efficiency and eurytopicity of SBSS,
even with population-scale sequencing for imputation.
Figure 3 The relationship between accuracy and sequence depth. The color-coded curves denote statistics at different kinds of sites (blue:
autosome, maternal-only heterozygous sites; red: autosome, paternal-only heterozygous sites; green: autosome, biparentally heterozygous sites;
orange: ChrX, maternal heterozygous sites).
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The dependence on cff-DNA concentration and
sequence depth also limits the application of SBSS to
early gestation. Therefore, it is an advisable strategy to
use the paternal haplotype for noninvasive fetal whole
genome recovery, especially for Mendelian disease
diagnosis.
Third, the results of the fetal genome recovery were
different between the three studies. Kitzman et al. and
Fan et al. focused on fetal genotype inference. We tried
to recover the fetal haplotype and genotype because the
haplotype information is important for complex diseases
screening, such as systemic lupus erythematosus [18].
Table 3 Comparison of fetal genome recovery methods






Trio strategy with corresponding grandparents
and CHS
Maternal: fosmid-based approach [26]
Paternal: could not be assessed due to




Strategy for fetal genome recovery
Paternalallele Two different alleles of fetal haplotype,
transmitted from the two parents, were
reconstructed by a HMM model in one step,
including transmitted chromosomes and
recombination breakpoints
SBSS SBSS+ imputation
Maternal allele For maternal-only heterozygous sites, they
used AIEto determine whole-block transitions
and HMM to identify assembly errors and
recombination breakpoints. For biparentally
heterozygous sites, maternal alleles were
determined by maternal-only heterozygous
sites within the same block
Allele imbalance estimated by
counting nucleotides specific
to each of the two maternal
alleles
Recovery of fetal genome
Genotype Yes Yes Yes




Table 4 Practical performance comparison between fetal genome recovery methods
Category Current study Kitzman et al. Fan et al.
Trio I1 Trio G1 P1T1 P1T2 P2T3
Gestational week 13 18.5 8.14 9 29 39
Estimated average cff-DNA concentration 5.69% 13%a 6%a 6%a 16%a 30%a
Average sequence depth (fold) 43.91 78a,b 56a,b 52.7 20.8 10.7
Fetal gender Male Male - Female Female Female
Maternal allele





Predicted rate 100% - - 71.60% 72.84% 72.94%
Prediction accuracy 98.57% - - 93.79% 95.84% 96.56%
Accuracy of inferred fetal genotype
Autosome Paternal-only heterozygous 99.12%, n = 65,409 96.8% 60.3% - - -
Maternal-only heterozygous 95.84%, n = 66,238 99.3%c 95.7%c - - -
Biparentally heterozygous 94.90%, n = 41,849 98.7%d 91.3%d - - -
ChrX Maternal-only heterozygous 98.45%, n = 1,932 - - - - -
- = No data
aApproximate.
bNon-duplicate.
cEstimated based on maternal phased sites.
dAccuracy of transmitted maternal allele prediction, estimated based on maternal phased sites.
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Besides helping in haplotype-related disease detection,
accurate fetal haplotype prediction might be helpful to
identify fetal de-novo copy number variations, such as
aneuploidy or even microdeletion and microduplication
syndromes (Additional file 1, Supplementary Materials).
Fourth, only Kitzman et al. performed a fetal de-novo
mutation identification. These mutations were expected
to appear within the maternal plasma as rare alleles, like
paternal-specific alleles [15]. Ideally, SBSS can identify
the fetal de-novo mutations easily. Therefore, Kitzman
et al. achieved 88.60% sensitivity of high-confidence
fetal de-novo mutations. However, the systematic error,
which was dominated by errors originating during poly-
merase chain reaction (PCR), introduced hundreds of
noisy signals. Even with stringent filters, >99% of the
candidate sites were false-positive, implying a specificity
of approximately 0.84% in trio I1. Moreover, as men-
tioned above, the sensitivity of SBSS depends on cff-
DNA concentration and sequence depth. In our case,
only 68.97% of the high-confidence fetal de-novo muta-
tions could be identified (Additional file 1, Table S4).
Hence, effective algorithms are still required for fetal de-
novo mutation identification.
In conclusion, all three of these methods provide pro-
mising solutions for non-invasive fetal genome recovery,
with different strengths and weaknesses. The performance
of paternal allele recovery indicated the requirement of the
paternal haplotype, especially for non-invasive Mendelian
disease detection. Therefore, it is wise to choose a suitable
approach to obtain the parental haplotype based on the
clinical reality, and our data show that a strategy with
additional relative samples would be an alternative
method. Our strategy of parental haplotype inference pro-
vided a practical solution to detect fetal Mendelian dis-
eases non-invasively, especially for couples with a born
proband.
Currently, it costs US$41 to generate a single gigabyte
of sequence data with the Illumina HiSeq 2000 platform
[28]; therefore, it would cost at least US$14,000 to gener-
ate the sequence data in this study. With developing
technology, the price of the sequencing will drop to US
$1,000 per genome in the foreseeable future [29]. Conse-
quently, sequence-based approaches will become practi-
cal for non-invasive fetal whole genome recovery.
Regarding Mendelian diseases, combining our method
with exome sequencing technology, it will cost only US
$1,200-1,400 for each family with a born proband
(including 30X exome sequence coverage for the couple,
the born proband, and the maternal plasma), which is
affordable for many families. Moreover, the developing
sequence platforms with shorter turnaround times will
significantly broaden the application of sequence-based
approaches for fetal genome recovery. For example, the
MiSeq platform takes <48 h for PE 150 sequencing,
meaning pregnant women could receive their results
within 1 week. Thus, the advantage of short turnaround
times makes us confident that sequence-based
approaches for fetal genome recovery will play an
increasingly important role in the future.
The development of non-invasive measures for fetal
genome recovery will surely bring new insight to prenatal
genetic diagnosis. In the case of fetal Mendelian disease
identification, sequence-based approaches will provide
fast and reliable options to pregnant women, reducing
the use of unnecessary invasive procedures. Comprehen-
sive fetal genome sequencing with high accuracy not only
enables us to make definitive diagnoses but also provides
potential applications in personal medicine, such as iden-
tification of allergens [30]. In addition, the easy sampling
of sequence-based approaches shows eurytopicity for
gestational stage, which may be helpful to make appro-
priate clinical decisions. For instance, a fetus diagnosed
with phenylketonuria in the third trimester would benefit
from treatment immediately after delivery [16]. However,
the increase in information available to parents will raise
ethical questions. For example, in most cases, the influ-
ence of a novel fetal mutation is hard to predict. Should a
woman be informed if her fetus has a novel mutation of
unpredictable consequence? The uncertainty of these
mutations may increase the unnecessary anxiety of preg-
nant women; however, the lack of such information
would lead to improper decisions. Thus, the key concern
is what kind of information would/should be reported,
and this question should be thoroughly discussed within
the scientific community and on a societal level.
There are still several limitations of our approach ham-
pering further clinical application. First, the use of com-
mercial microarrays (grandparents or the CHS trios)
greatly restricted our study of common SNPs. Therefore,
only a small fraction of SNPs were discussed in our study,
and we ignored most of the rare variations. In addition,
short indels, which could not be located in the parental
haplotypes because of the lack of grandparental informa-
tion, were excluded from our analysis. Short indels not
only play an important role in Mendelian disease [31] but
also show strong power as markers [32]. At present, target
sequences with abundant tag-SNPs are advisable for future
studies. Second, our study focused on mutations at the
DNA level, which excluded most of the haplotype-asso-
ciated transgenerational epigenetic modifications [33]. The
clinical application of fetal genome recovery will require
more robust experimental breakthroughs and algorithms
to explore the comprehensiveness of the genome coverage.
Third, although we successfully recovered a fetal genome
in a case of a singleton pregnancy, accurate genome recov-
ery in cases of twin pregnancy is still unattainable.
Currently, the sequence-based approach for non-invasive
prenatal diagnosis in twin pregnancies is restricted to
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aneuploidy [34]. The recovery of twins’ genomes will
greatly broaden the horizon of non-invasive prenatal
diagnosis.
Conclusions
In this study, we introduced an accurate method for
fetal genome recovery in one step using maternal
plasma sequencing. More than 95% of the fetal geno-
types were inferred successfully, and most importantly,
>95% of the fetal haplotypes were recovered precisely.
As a proof of concept, we propose the clinical applica-
tion of the recovered genome to non-invasive prenatal
diagnosis/screening. In summary, we report an accurate
and easy method for non-invasive fetal whole genome
recovery by maternal plasma sequencing. An accurate
fetal haplotype would enhance the dimensionality of
fetal variation detection in prenatal diagnosis/screening
and promote the development of fetal medicine. Our
results indicate the potential of using sequencing tech-
nology in prenatal diagnosis, and they should accelerate
the application of sequencing technology in clinical
trials.
Additional material
Additional file 1: Supplementary materials. This file provides a
detailed description of the experimental work and bioinformatics
methods of this study (SNP calling, parental haplotype construction, fetal
genome recovery). We also performed comprehensive maternal plasma
DNA profiling (section 2). This file further contains supplementary Figures
S1-5 and Tables S1-3: Figure S1, ‘The size distribution of plasma DNA’,
shows the size distribution of maternal and fetal DNA fragments in DNA.
Figure S2, ‘The GC content of plasma DNA segments’, shows the GC
consistency between maternal and paternal DNA segments in plasma.
Figure S3, The sequence depth of paternal-specific alleles’, shows the
sequence depth distribution of paternal-specific alleles in maternal
plasma. Figure S4, ‘The distribution of the concentration difference
between allele 0 and allele 1’, shows the concentration difference
between the maternal alleles in plasma. Table S1, ‘The consistency
between SNP calling using NGS data and the Illumina 2.5M array’, shows
the SNP calling consistency between NGS and the SNP-array. Table S2,
‘The average of estimated concentration of each allele on different
chromosomes’, shows the average concentration of each allele on
different chromosomes calculated by MLE. Table S3, ‘The cff-DNA
concentration of each chromosome based on paternal-specific alleles’,
shows the average cff-DNA concentration on each chromosome. Table
S4, ‘The read distribution of fetal de-novo mutations’, shows the
distribution of reads in plasma sequences at high-confidence fetal de-
novo mutation sites. Table S5, ‘The type III errors’, lists detailed
information of the type III errors of fetal genome recovery.
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